Compare Divis Laboratories with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs SUN PHARMA - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES SUN PHARMA DIVIS LABORATORIES/
SUN PHARMA
 
P/E (TTM) x 58.8 133.5 44.0% View Chart
P/BV x 13.5 3.1 442.8% View Chart
Dividend Yield % 0.5 0.7 64.9%  

Financials

 DIVIS LABORATORIES   SUN PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
SUN PHARMA
Mar-20
DIVIS LABORATORIES/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,639484 338.6%   
Low Rs1,115315 353.7%   
Sales per share (Unadj.) Rs186.3136.9 136.1%  
Earnings per share (Unadj.) Rs51.017.5 292.0%  
Cash flow per share (Unadj.) Rs57.326.0 220.4%  
Dividends per share (Unadj.) Rs16.004.00 400.0%  
Dividend yield (eoy) %1.21.0 116.1%  
Book value per share (Unadj.) Rs261.8188.7 138.8%  
Shares outstanding (eoy) m265.472,399.26 11.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.42.9 253.1%   
Avg P/E ratio x27.022.9 118.0%  
P/CF ratio (eoy) x24.015.4 156.3%  
Price / Book Value ratio x5.32.1 248.3%  
Dividend payout %31.422.9 137.0%   
Avg Mkt Cap Rs m365,592958,864 38.1%   
No. of employees `00011.817.8 66.7%   
Total wages/salary Rs m5,42363,624 8.5%   
Avg. sales/employee Rs Th4,175.118,490.6 22.6%   
Avg. wages/employee Rs Th457.73,582.6 12.8%   
Avg. net profit/employee Rs Th1,141.82,357.6 48.4%   
INCOME DATA
Net Sales Rs m49,463328,375 15.1%  
Other income Rs m1,5566,360 24.5%   
Total revenues Rs m51,019334,735 15.2%   
Gross profit Rs m18,71869,898 26.8%  
Depreciation Rs m1,68920,528 8.2%   
Interest Rs m353,027 1.2%   
Profit before tax Rs m18,55152,702 35.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,606 0.0%   
Tax Rs m5,0238,228 61.1%   
Profit after tax Rs m13,52741,868 32.3%  
Gross profit margin %37.821.3 177.8%  
Effective tax rate %27.115.6 173.4%   
Net profit margin %27.312.8 214.5%  
BALANCE SHEET DATA
Current assets Rs m46,501316,542 14.7%   
Current liabilities Rs m8,468157,064 5.4%   
Net working cap to sales %76.948.6 158.3%  
Current ratio x5.52.0 272.5%  
Inventory Days Days13188 149.4%  
Debtors Days Days86105 82.0%  
Net fixed assets Rs m25,797243,102 10.6%   
Share capital Rs m5312,399 22.1%   
"Free" reserves Rs m68,962450,245 15.3%   
Net worth Rs m69,493452,645 15.4%   
Long term debt Rs m020,289 0.0%   
Total assets Rs m80,383682,525 11.8%  
Interest coverage x531.018.4 2,884.6%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.5 127.9%   
Return on assets %16.96.6 256.5%  
Return on equity %19.59.2 210.4%  
Return on capital %26.711.2 238.1%  
Exports to sales %00-   
Imports to sales %24.60-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m12,187NA-   
Fx inflow Rs m41,23874,219 55.6%   
Fx outflow Rs m12,40527,964 44.4%   
Net fx Rs m28,83346,255 62.3%   
CASH FLOW
From Operations Rs m9,54365,548 14.6%  
From Investments Rs m-6,854-25,888 26.5%  
From Financial Activity Rs m-2,459-57,151 4.3%  
Net Cashflow Rs m230-13,857 -1.7%  

Share Holding

Indian Promoters % 52.0 63.7 81.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 5.1 230.0%  
FIIs % 19.0 23.0 82.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 8.3 207.2%  
Shareholders   31,796 133,026 23.9%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   SHASUN PHARMA  WYETH  GSK PHARMA  ALEMBIC  DR. REDDYS LAB  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Plunges 746 Points; Banking & Metal Stocks Bleed(Closing)

Indian share markets witnessed huge selling pressure today and extended losses as the session progressed, dragged down by heavy selling in metal and banking stocks.

Related Views on News

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jan 22, 2021 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - ALKEM LABORATORIES COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS